SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Assurant held its Annual Meeting of Stockholders and disclosed the voting results for five proposals, including director elections, auditor ratification, executive compensation advisory vote, and stockholder proposals.
View raw filing on EDGAR →Stockholders approved an amendment to the Assurant, Inc. 2017 Long Term Equity Incentive Plan increasing the share reserve by 480,000 shares, expanding the equity grants available to officers and directors.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on three proposals: election of seven directors, advisory approval of executive compensation (Say-on-Pay), and ratification of Grant Thornton LLP as independent auditor. All three proposals passed, with detailed vote tallies provided for each nominee and proposal. This is a material disclosure as it confirms the composition of the board and auditor selection for the fiscal year.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Travel & Leisure Co.'s 2026 Annual Meeting held on May 20, 2026. The filing reports final voting tallies for three proposals: election of nine directors, advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. This is a quintessential Item 5.07 shareholder vote results disclosure, material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →ServiceNow held its Annual Meeting of shareholders and disclosed complete voting results across six proposals, including director elections, advisory votes on executive compensation and frequency, auditor ratification, equity plan amendments, and a shareholder proposal.
View raw filing on EDGAR →The filing discloses the imminent consummation of a material acquisition: DB Insurance Co., Ltd. is acquiring Fortegra (a Tiptree subsidiary) for $1.65 billion in cash pursuant to a Merger Agreement executed on September 26, 2025. The parties expect to close on May 29, 2026, subject to customary closing conditions. This represents a significant disposition of a major subsidiary and constitutes a material M&A event under Item 1.01/2.01 standards.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of First Guaranty Bancshares' annual shareholder meeting held May 21, 2026, including election of seven directors, an advisory vote on executive compensation, and ratification of EisnerAmper, LLP as independent auditor. All proposals were approved by shareholders. This is a classic shareholder vote results disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →EchoStar completed the "Spectrum Transfer Closing" on May 22, 2026, whereby subsidiaries transferred spectrum rights and licenses (50 MHz across multiple frequency ranges plus up to 15 MHz of AWS spectrum) to a trust as part of a multi-step transaction with Space Exploration Technologies Corp. This constitutes a material disposition of significant spectrum assets, which are core assets for a satellite/communications company. The transaction structure and magnitude (involving spectrum licenses and substantial consideration) qualifies as material M&A activity under Item 1.02/2.01 framework, even though disclosed under Item 8.01.
View raw filing on EDGAR →Shareholders approved an Amended and Restated 2020 Equity Incentive Plan with material changes including an increase in available shares from 520,000 to 820,000 and an increase in the annual compensation limit for non-employee directors from $150,000 to $175,000.
View raw filing on EDGAR →First Northwest Bancorp held its 2026 Annual Meeting on May 19, 2026, with voting results on five proposals: election of nine directors (passed), approval of amended articles of incorporation (failed at 67.37%), approval of amended equity incentive plan (passed at 90.38%), advisory vote on executive compensation (passed at 84.64%), and ratification of auditor Baker Tilly US, LLP (passed at 94.11%).
View raw filing on EDGAR →The Board adopted a stock repurchase program authorizing repurchases of up to 5% of common stock over the next twelve months. While share repurchases are material capital allocation decisions that affect shareholder value and earnings per share, this disclosure does not fit neatly into the more specific event categories (it is not an earnings release, M&A activity, executive change, impairment, or other defined event type). The announcement is material to investors as it signals management's confidence and capital deployment strategy, but lacks a dedicated taxonomy entry.
View raw filing on EDGAR →MainStreet Bancshares held its 2026 Annual Meeting of Shareholders on May 21, 2026, with voting results on three proposals: election of four directors (Jeff W. Dick, Paul Thomas Haddock, Wendy Adeler Hall, and Terry M. Saeger), ratification of Yount, Hyde & Barbour, P.C. as independent auditor, and advisory approval of named executive officer compensation.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of RBB Bancorp's 2026 Annual Meeting of Shareholders held on May 21, 2026. The filing presents detailed vote tallies for three proposals: election of nine directors, advisory approval of named executive officer compensation, and ratification of Crowe LLP as independent auditor. All three proposals passed with substantial majorities, making this a routine but material shareholder governance event.
View raw filing on EDGAR →Hecla Mining held its Annual Meeting of Shareholders on May 21, 2026, with voting results on four proposals: election of two directors, ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the nonemployee director stock plan. All proposals passed with substantial majorities.
View raw filing on EDGAR →The disclosure announces acceptance of an abstract featuring pooled cardiac safety data for Annamycin (the company's lead drug candidate) for poster presentation at the 2026 ASCO Annual Meeting. For a clinical-stage biotech company, positive clinical data presentations at major medical conferences are material to investors assessing development progress and regulatory pathway viability. However, this does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, impairment, or litigation), so "other_material" is most appropriate.
View raw filing on EDGAR →Ryan Hansen was appointed to the position of President on May 18, 2026, having previously served as Executive Vice President since November 2023. While the disclosure also includes compensatory arrangements (stock options, PSUs, and a salary increase), the principal disclosed action is the appointment to a senior executive role. This is material as it represents a significant change in the Company's leadership structure.
View raw filing on EDGAR →LGL Group announced a rights offering to distribute transferable subscription rights to common stockholders, allowing them to purchase up to 6,540,435 shares of Common Stock at a fixed subscription price pursuant to a Form S-1 registration statement. This material dilutive equity issuance will increase share count and potentially dilute existing shareholders.
View raw filing on EDGAR →Clene Inc. amended senior secured convertible promissory notes by extending the maturity date to August 13, 2027 and deferring monthly principal and interest payments of $150,000 scheduled to commence September 2026. The deferral of debt service payments signals financial stress and materially restructures the Company's direct financial obligations.
View raw filing on EDGAR →Clene Inc. held its Annual Meeting of Stockholders on May 21, 2026, with shareholders voting on four proposals: election of Class III directors (Robert Etherington, Shalom Jacobovitz, Alison H. Mosca), ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2020 Stock Plan increasing authorized shares by 1,000,000. All proposals received detailed vote tallies and were approved.
View raw filing on EDGAR →Investar Holding Corporation held its 2026 Annual Meeting of shareholders on May 20, 2026, with voting results on five proposals: election of 13 directors, ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, frequency of future advisory votes on compensation, and approval of the Second Amended and Restated 2017 Long-Term Incentive Compensation Plan.
View raw filing on EDGAR →William M. Clancy, Executive Vice President and Chief Financial Officer, notified the Company of his retirement and resignation effective December 31, 2026. The departure includes severance, bonus, and RSU vesting arrangements.
View raw filing on EDGAR →Vishay Precision Group held its 2026 Annual Meeting of Stockholders on May 19, 2026, with final voting results disclosed for three proposals: election of six directors, ratification of Brightman Almagor Zohar & Co. as independent auditor, and an advisory vote on executive compensation.
View raw filing on EDGAR →The filing discloses two material definitive agreements entered into by the Fund: a Custodial Services Agreement with BitGo Bank & Trust for bitcoin safekeeping and a Master Purchase Agreement with BitGo Prime for bitcoin trading services. While these are operational agreements essential to the Fund's bitcoin holdings and trading activities, they do not constitute a traditional M&A transaction (acquisition, disposition, merger, or change of control). The agreements establish critical infrastructure for the Fund's operations but lack the transformative character typical of ma_activity events. This is best classified as other_material given the material nature of the agreements to the Fund's operations but their operational rather than transactional character.
View raw filing on EDGAR →Nathan D. Knuth resigned from the Company's Board of Directors effective at the end of the 2026 Annual Meeting on May 21, 2026, citing other professional commitments.
View raw filing on EDGAR →Shareholders voted at the 2026 Annual Meeting on May 21, 2026, approving three proposals: election of James J. Seifert and Colleen R. Skillings as directors, ratification of Olsen, Thielen & Company, Ltd. as independent auditor, and approval of a shareholder proposal, all with substantial majorities.
View raw filing on EDGAR →Live Oak Bancshares held its 2026 Annual Meeting of Shareholders on May 19, 2026, with voting results on five matters: election of ten directors, approval of the 2026 Omnibus Stock Incentive Plan and 2026 Employee Stock Purchase Plan, an advisory vote on named executive officer compensation, and ratification of KPMG as independent auditor.
View raw filing on EDGAR →The filing discloses financial results for the first fiscal quarter ended March 31, 2026, via a press release attached as exhibit 99.1. Item 2.02 is the standard disclosure vehicle for earnings releases, and the prose explicitly states "the Company issued a press release setting forth the financial results." This is a material event affecting investor assessment of the registrant's operational performance.
View raw filing on EDGAR →This is a straightforward auditor change: M. S. Madhava Rao resigned as the independent registered public accounting firm on May 13, 2026, and was immediately replaced by GSKCA & Associates. The filing explicitly discloses the resignation, acceptance by the Board, and engagement of the successor auditor under Item 4.01. While the prior auditor's reports contained going-concern language, the primary disclosed event is the change in auditors itself, making auditor_change the appropriate classification.
View raw filing on EDGAR →Classover Holdings entered into a ChEF Purchase Agreement with Chardan Capital Markets LLC providing the right to issue and sell up to $100 million in newly issued shares of Class B common stock at a 4.0% discount to volume-weighted average price, subject to Nasdaq Exchange Cap limitations (19.99% of outstanding shares) and beneficial ownership caps (4.99%-9.99%).
View raw filing on EDGAR →The filing discloses the Company's failure to comply with a Market Capitalization Covenant under senior secured convertible notes totaling $9.9 million, triggering a 10% penalty on outstanding principal and granting the lender conversion rights. Although a waiver was obtained, the underlying breach of a material debt covenant is the principal disclosed event and represents a significant financial stress indicator for a reasonable investor.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the Company's May 20, 2026 annual meeting of shareholders. The filing reports final voting tallies for two proposals: (1) election of nine directors to the Board, with detailed vote counts and percentages for each nominee, and (2) an advisory vote to approve named executive officer compensation, which passed with 98.05% approval. This is a textbook Item 5.07 disclosure of shareholder meeting results, which is material to investors as it confirms board composition and executive compensation approval.
View raw filing on EDGAR →LyondellBasell held its Annual Meeting of shareholders on May 22, 2026, with voting results on nine proposals including director elections, auditor appointments, executive compensation advisory vote, and authorization of a share repurchase program of up to 10% of issued share capital (34,042,250 shares) through November 22, 2027.
View raw filing on EDGAR →Shareholders approved amendments to the LyondellBasell Industries Long Term Incentive Plan, authorizing an additional 8,000,000 ordinary shares for issuance and establishing per annum grant limits of $2 million for non-executive directors.
View raw filing on EDGAR →This 8-K discloses the results of Trio Petroleum's annual meeting of stockholders held on May 21, 2026, under Item 5.07. The filing reports voting outcomes on four proposals: election of a Class III director (Robin Ross), approval of a reverse stock split (1:2 to 1:10 ratio), amendment to the 2022 Equity Incentive Plan to increase reserved shares by 3.5 million, and ratification of Bush & Associates CPA LLC as independent auditor. All proposals passed by majority vote, making this a standard shareholder vote results disclosure.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from MAIA Biotechnology's 2026 Annual Meeting held on May 21, 2026, filed under Item 5.07. The filing reports voting outcomes for two proposals: (1) election of Class I directors (Louie Ngar Yee and Steven Chaouki re-elected) and (2) ratification of Grant Thornton LLP as independent auditor, with specific vote tallies for each matter. This is a routine but material governance disclosure required by Item 5.07.
View raw filing on EDGAR →The filing discloses that Cayson Acquisition Corp's insiders deposited a $125,000 contribution on May 21, 2026, as the third monthly installment required under a shareholder-approved extension of the business combination deadline to March 23, 2027. While this relates to a SPAC's extension mechanism and insider funding, it does not cleanly fit the standard taxonomy categories (not an M&A completion, not a shareholder vote result per se, not a covenant breach). The contribution to the trust account is material to investors assessing the company's runway and commitment to completing a business combination, but the event is primarily administrative in nature—a routine funding deposit under a previously approved extension plan.
View raw filing on EDGAR →Item 3.01 discloses that GT Biopharma received notice from Nasdaq on May 20, 2026, granting an additional 180-day compliance period (until November 16, 2026) to regain compliance with the minimum bid price requirement of $1.00 per share. The company's stock had previously fallen below this threshold for 30 consecutive business days. This is a classic delisting risk disclosure—the company faces potential removal from Nasdaq if it cannot restore its stock price above $1.00 within the extended cure period.
View raw filing on EDGAR →The filing discloses the appointment of Tyler Evans, Chief Investment Officer, as a Class II director on May 21, 2026, following Board approval to expand from six to seven directors. While the filing also covers a 1-for-40 reverse stock split (Item 5.03), the substantive executive action is the director appointment. Evans will not receive additional compensation and does not qualify as independent, but the appointment itself is a material change to Board composition that would affect investor assessment of governance.
View raw filing on EDGAR →Mr. Paul Stuka, the current Chair of the Board and Chair of the Compensation Committee, notified the Company on May 20, 2026 of his decision to not seek reelection and to retire from the Board at the 2027 Annual Meeting. This is a material departure of a senior director and board leadership position, disclosed under Item 5.02.
View raw filing on EDGAR →The filing discloses under Item 4.01 that Integrität Audit, Accounting & Advisory, LLC resigned as the independent registered public accounting firm on May 19, 2026, without completing the audit for fiscal year ended December 31, 2025. Simultaneously, M&K CPAs, PLLC was appointed as the new independent registered public accounting firm on May 21, 2026. This is a classic auditor change event material to investors assessing financial reporting reliability.
View raw filing on EDGAR →Akari Therapeutics entered into a securities purchase agreement on May 20, 2026 to sell 1,470,588 unregistered ADSs (or pre-funded warrants) plus multiple series of warrants in a private placement for approximately $5.5 million gross proceeds. This unregistered equity issuance under Section 4(a)(2) and Regulation D includes significant warrant coverage that will further dilute shareholders upon exercise.
View raw filing on EDGAR →Peace Acquisition Corp is a SPAC (special purpose acquisition company) that has completed its initial public offering on May 21, 2026, as evidenced by the effective Registration Statement on Form S-1 and the entry into material definitive agreements including underwriting agreements, warrant agreements, and private placement purchase agreements. While the filing is technically structured as Item 1.01 (Entry into Material Definitive Agreement), the substance reflects the foundational transaction of a SPAC formation and IPO, which constitutes material acquisition-related activity under the taxonomy's ma_activity category.
View raw filing on EDGAR →Mike Powell's departure from his role as Chief Innovation Officer, effective May 29, 2026, is the principal disclosed event. The filing explicitly states the departure date and the notice received on May 18, 2026. As a C-suite officer responsible for technology leadership, this departure is material to investors assessing the company's executive stability and strategic direction, particularly given the company's reference to providing an update on "enhanced technology leadership" at its June 15 earnings call.
View raw filing on EDGAR →Ensysce Biosciences received notice from Nasdaq on May 21, 2026, that it is subject to delisting due to non-compliance with the $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan or face delisting, with a potential 180-day extension if the plan is accepted. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →Item 2.02 discloses a press release issued on May 18, 2026 announcing financial results for the quarter ending March 31, 2026, along with operational highlights. The filing explicitly references the press release as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly financial performance and operational updates.
View raw filing on EDGAR →The filing discloses a Nasdaq notice of non-compliance with Listing Rule 5250(c)(1) due to failure to timely file the Form 10-Q for the period ended March 31, 2026. While the notice has no immediate effect on listing, the company has 60 calendar days to submit a compliance plan or face potential delisting. This is a material disclosure of delisting risk under Item 3.01.
View raw filing on EDGAR →The filing discloses a settlement agreement under which FOXO Technologies issued 400 shares of Series D Preferred Stock (convertible into Class A Common Stock) plus $175,000 in cash payments to J.H. Darbie & Co., Inc. Item 3.02 explicitly addresses "Unregistered Sales of Equity Securities" and notes the issuance was made under Section 4(a)(2) and Regulation D. The convertible preferred stock and potential conversion of unpaid cash balances into common stock at 90% of VWAP represent dilutive equity issuances typical of settlement arrangements at smaller issuers.
View raw filing on EDGAR →The filing discloses entry into a Third Amendment to Securities Purchase Agreement and Junior Convertible Notes on May 22, 2026, which materially amends the terms of convertible debt instruments. The amendments include deferral of installment payments to July 2026, addition of anti-dilution provisions, removal of redemption requirements, and extension of investor participation rights to December 2027. While this is a debt restructuring rather than a traditional M&A transaction, it represents a material definitive agreement under Item 1.01 that would affect investor assessment of the company's capital structure and financial obligations.
View raw filing on EDGAR →The filing discloses the appointment of Theodore P. Botts as a member of the Board of Directors on May 19, 2026, to fill a vacancy. The disclosure includes his extensive background in investment banking and finance, and the Company entered into a Director Agreement and Indemnification Agreement providing for an annual fee of $75,000 payable in shares. This is a material executive appointment affecting the composition and governance of the registrant's board.
View raw filing on EDGAR →Laser Photonics received a notice from Nasdaq on May 21, 2026, stating non-compliance with continued listing rules due to failure to file the Form 10-Q for the period ended March 31, 2026. The company has 60 days to submit a compliance plan, with a maximum 180-day cure period ending November 16, 2026. This is a direct delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →